Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr
about
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanomaSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibTreatment of metastatic melanoma: an overviewChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant MelanomaEstrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical UtilityDacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)Drug delivery nanoparticles in skin cancersRoutine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trialsA phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaPhase II assessment of talabostat and cisplatin in second-line stage IV melanoma.Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Treatment of malignant melanoma.Estrogen receptor-alpha methylation predicts melanoma progressionA randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.Malignant melanoma (metastatic)Melanoma: a model for testing new agents in combination therapies.Smad7 restricts melanoma invasion by restoring N-cadherin expression and establishing heterotypic cell-cell interactions in vivo.Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes.Metastatic melanoma: chemotherapy to biochemotherapy.The history and future of chemotherapy for melanoma.HSPPC-96 vaccine in metastatic melanoma patients: from the state of the art to a possible future.Socioeconomic status and chemotherapy use for melanoma in older people.Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-makingA single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.A review of evidence-based treatment of stage IIB to stage IV melanoma.A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.Lung metastases from melanoma: when is surgical treatment warranted?Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma.Immunotherapy of distant metastatic disease.Molecular-targeted therapy in malignant melanoma.Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses.The role of debulking surgery in metastatic melanoma.Sorafenib in melanoma.Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors.Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics.
P2860
Q24246409-88F8A6E8-AFA8-4733-8719-9616541D6945Q24594790-2FAA3EB6-F3C7-4B94-B45D-831699F7ED10Q24642384-4CAC9CC5-FE6F-479A-98ED-A76AF9EECCDAQ26770492-BDEF18ED-169B-489B-A709-E6CFB93CE064Q28074939-FB656115-7326-40DD-B971-A56164CB4905Q28078465-C61127A3-8285-4AFB-A2B4-1FA6A6296769Q28362951-868A18EA-1918-45BE-8B53-6A935FB2CA06Q28390405-8861AF0F-5F79-4B8D-B49C-76C4DD8AC4ACQ28730438-B20D446C-1AEB-4BA2-8596-400ACB22E10DQ33373492-8F546CED-8662-48BF-AB0C-72E2DC345455Q33488712-CC56BFD9-625D-4442-A67D-4705E4AAA105Q33667485-4F32FB28-FC16-405D-8F13-67515F1845F0Q33689227-A78E942A-08F4-4861-B956-361C0621338BQ33797076-7798D076-53FA-4D23-91D2-4BD009F4AD3AQ33797499-5C388C22-6988-469C-9CF8-571602D49A87Q33850507-74F935BF-93D1-45A4-82CD-192A9081DE3EQ33863916-F747B0EB-134C-474A-9FB5-DF9CB7350A7CQ34285551-DFBE6398-44BA-480A-884B-9C3584AEA900Q34436139-AD41605A-96AF-4288-9842-D552408E718AQ34573040-721D9740-18AD-4F56-A7D9-14BB3184CF0EQ34608084-BA8D5942-8778-4A1D-97F5-E7F847D76772Q35009889-A3873E83-D920-472E-85C5-459948E30D41Q35050922-2B65EC8E-4DAC-4B18-BAF9-93325B687DC1Q35056525-E946E160-4CEE-466D-A92F-5E367DD9E870Q35073752-8A95F596-2433-4973-8C99-8340A96AC83FQ35632517-914D6F02-3CC8-4819-A211-8C14EE507106Q35728471-BA0D708A-46FB-4643-AE2F-94980832B7BCQ36229746-31DD9928-DAF5-4048-AA81-0F5469F79B38Q36621278-7C5759E0-3E3E-49D9-B949-B908BBD4BAD4Q36621809-30360649-49F2-406E-AC90-4A363D47FC9EQ36643649-F1A055E9-265D-477F-B94D-1B5071C793D1Q36984477-DFAEBFFB-8F8F-4C56-8F9C-A2D376A54200Q37182228-C5C44B98-D87C-4F3A-83D5-5AB2CA2E2E0BQ37266668-9FAD6EB5-63F2-4EA4-A4BA-BF555EB13DC6Q37483949-9CECA75D-16F8-479B-8E42-A7FE05C883F2Q37577095-EFE78124-E38F-4D69-AEF6-4016A5E7A697Q37582966-27296D65-ED55-4400-91E4-838AE71B2C24Q37990977-9E00C627-99B2-41A4-9D6A-0B3E098AE880Q38088409-0AA82ED8-813C-4E38-ABF2-B75363EC48FCQ38127412-FF2E046C-C04D-48BF-9507-98A5D0B1204C
P2860
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@ast
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@en
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@nl
type
label
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@ast
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@en
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@nl
prefLabel
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@ast
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@en
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@nl
P2093
P1476
Phase III trial of dacarbazine ...... astern Cooperative Oncology Gr
@en
P2093
A S Coates
C I Falkson
J M Kirkwood
M B Atkins
P304
P356
10.1200/JCO.1998.16.5.1743
P407
P577
1998-05-01T00:00:00Z